Harmony Biosciences Holdings, Inc.(HRMY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HRMY Harmony Biosciences Holdings, Inc.

Trading 01-20 09:52:21 EST

36.33

+0.11

+0.30%

High36.33	Low35.16	Vol27.27K
Open35.85	D1 Closing36.22	Amplitude3.23%
Mkt Cap2.09B	Tradable Cap1.62B	Total Shares57.60M
T/O975.31K	T/O Rate0.06%	Tradable Shares44.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"HRMY","market":"US","secType":"STK","nameCN":"Harmony Biosciences Holdings, Inc.","latestPrice":36.33,"timestamp":1768920731689,"preClose":36.22,"halted":0,"volume":27271,"delay":0,"changeRate":0.0030369961347321765,"floatShares":44560063,"shares":57596358,"eps":3.167729,"marketStatus":"Trading","change":0.11,"latestTime":"01-20 09:52:21 EST","open":35.85,"high":36.33,"low":35.16,"amount":975312.871727,"amplitude":0.032303,"askPrice":36.33,"askSize":23,"bidPrice":36.05,"bidSize":100,"shortable":3,"etf":0,"ttmEps":3.167729,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768942800000},"marketStatusCode":2,"adr":0,"listingDate":1597809600000,"exchange":"NASDAQ","adjPreClose":36.22,"preHourTrading":{"tag":"盘前","latestPrice":35.77,"preClose":36.22,"latestTime":"09:29 EST","volume":1187,"amount":42253.371925,"timestamp":1768919399999,"change":-0.45,"changeRate":-0.012424,"amplitude":0.018285},"postHourTrading":{"tag":"盘后","latestPrice":36.22,"preClose":36.22,"latestTime":"18:05 EST","volume":28622,"amount":1036689.61,"timestamp":1768604741087,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.539289,"impliedVol":0.5461,"impliedVolPercentile":0.3745},"requestUrl":"/m/hq/s/HRMY/wiki","defaultTab":"wiki","newsList":[{"id":"2604190270","title":"Harmony Biosciences : Needham Raises Target Price to $46 From $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190270?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:19","pubTimestamp":1768911563,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL0XD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HRMY","BK4007"],"gpt_icon":0},{"id":"2603685699","title":"Harmony Biosciences Holdings (HRMY) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2603685699","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603685699?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:37","pubTimestamp":1768304228,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Harmony Biosciences Holdings, with a price target of $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/harmony-biosciences-holdings-hrmy-receives-a-buy-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/harmony-biosciences-holdings-hrmy-receives-a-buy-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HRMY","BK4007"],"gpt_icon":0},{"id":"2602510412","title":"BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510412","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510412?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:13","pubTimestamp":1768223630,"startTime":"0","endTime":"0","summary":"BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value CreationJan 12 (Reuters) - Harmony Biosciences Hold","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY","BK4007"],"gpt_icon":0},{"id":"2602510605","title":"Harmony Biosciences Q4 Prelim Unaudited Net Product Revenue $243 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510605?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:05","pubTimestamp":1768223133,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HRMY","BK4007"],"gpt_icon":0},{"id":"2602106755","title":"Harmony Biosciences: Wakix Net Revenue Projected Between $1.0 Bln - $1.04 Bln for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602106755","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602106755?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:05","pubTimestamp":1768223133,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SU:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","HRMY"],"gpt_icon":0},{"id":"2602751099","title":"Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602751099","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602751099?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:05","pubTimestamp":1768223129,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings Inc. announced preliminary, unaudited net product revenue for WAKIX of approximately $243 million for the fourth quarter and $868 million for the full year 2025, reflecting continued strong growth. The company provided guidance for 2026 WAKIX net revenue in the range of $1.0 to $1.04 billion, positioning the drug for blockbuster status in narcolepsy. This outlook marks a significant increase in revenue expectations compared to the previous year, demonstrating ongoing commercial momentum and expansion of the pitolisant franchise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire  on January 12, 20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3Jx3Bb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HRMY"],"gpt_icon":0},{"id":"2602399060","title":"Harmony Biosciences Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602399060","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602399060?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:12","pubTimestamp":1767892320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HRMY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 12:12 ET (17:12 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY","BK4007"],"gpt_icon":0},{"id":"2601364330","title":"Harmony Biosciences price target lowered to $45 from $48 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364330","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364330?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:55","pubTimestamp":1767876937,"startTime":"0","endTime":"0","summary":"Truist lowered the firm’s price target on Harmony Biosciences (HRMY) to $45 from $48 and keeps a Buy rating on the shares. The firm updated its mod...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/harmony-biosciences-price-target-lowered-to-45-from-48-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/harmony-biosciences-price-target-lowered-to-45-from-48-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HRMY","BK4007"],"gpt_icon":0},{"id":"2601032608","title":"Harmony Biosciences to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601032608","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601032608?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:05","pubTimestamp":1767791114,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Jeffrey M. Dayno, M.D., President and Chief Executive Officer, is scheduled to present on Tuesday, January 13, 2026, at 4:30 p.m. PT / 7:30 p.m. ET. A webcast of the presentation will be available on the investor page of the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire  on January 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL3gCpn0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY","BK4007"],"gpt_icon":0},{"id":"2592462689","title":"Jeffrey M. Dayno, President and CEO, Reports Disposal of Harmony Biosciences Holdings Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592462689","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592462689?lang=en_us&edition=fundamental","pubTime":"2025-12-18 06:25","pubTimestamp":1766010336,"startTime":"0","endTime":"0","summary":"Jeffrey M. Dayno, President and CEO of Harmony Biosciences Holdings Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL2nRD8T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Jeffrey M. Dayno, President and CEO, Reports Disposal of Harmony Biosciences Holdings Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HRMY"],"gpt_icon":0},{"id":"2591412986","title":"BRIEF-Beacon Biosignals Announces Partnership With Harmony Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2591412986","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591412986?lang=en_us&edition=fundamental","pubTime":"2025-12-16 19:31","pubTimestamp":1765884685,"startTime":"0","endTime":"0","summary":"BRIEF-Beacon Biosignals Announces Partnership With Harmony Biosciences Dec 16 (Reuters) - Harmony Biosciences Holdings Inc HRMY.O:BEACON BIOSIGNALS ANNOUNCES PARTNERSHIP WITH HARMONY BIOSCIENCES TO AD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8NLJ53:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY","BK4007"],"gpt_icon":0},{"id":"2591431986","title":"Harmony Biosciences Partners with Beacon Biosignals to Advance EEG-Based Sleep Disorder Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2591431986","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591431986?lang=en_us&edition=fundamental","pubTime":"2025-12-16 19:30","pubTimestamp":1765884633,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on December 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLtz5Z0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU0314104364.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014039.USD","SG9999014005.SGD","IE00BKPKM429.USD","BK4588","BK4585","HRMY","IE00B64PRP62.GBP","LU2210149790.SGD","BK4007","LU2210150020.SGD","NDAQ","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2591986160","title":"Beacon Biosignals Announces Partnership With Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative Eeg","url":"https://stock-news.laohu8.com/highlight/detail?id=2591986160","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591986160?lang=en_us&edition=fundamental","pubTime":"2025-12-16 19:30","pubTimestamp":1765884600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8NLJ53:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","HRMY"],"gpt_icon":0},{"id":"2590321725","title":"Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590321725","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590321725?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:11","pubTimestamp":1765314665,"startTime":"0","endTime":"0","summary":"Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLc3gXMt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HRMY"],"gpt_icon":0},{"id":"2589353622","title":"Harmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353622","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353622?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199125,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings Inc. has announced initial data from the open-label extension  of its ongoing Phase 3 ARGUS trial, which is evaluating EPX-100  for the treatment of Dravet syndrome. The data, to be presented at the 2025 American Epilepsy Society Annual Meeting in December, showed that participants with at least six months of exposure to EPX-100 experienced a median reduction of approximately 50% in countable motor seizure frequency per 28 days. Half of the participants achieved at least a 50% reduction in seizure frequency. EPX-100 was generally well-tolerated, with the most common adverse events being seizures, pyrexia, and upper respiratory tract infection. No significant gastrointestinal adverse events were reported. The ARGUS and LIGHTHOUSE trials for EPX-100 are ongoing, with topline data from ARGUS expected in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL76YTwB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HRMY"],"gpt_icon":0},{"id":"2589306859","title":"Harmony Biosciences (HRMY) Is Up 7.6% After GR Pitolisant Bioequivalence Win and Patent Runway Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2589306859","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589306859?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:23","pubTimestamp":1764894219,"startTime":"0","endTime":"0","summary":"Harmony Biosciences recently reported positive pivotal bioequivalence results for its gastro-resistant (GR) pitolisant formulation, confirming equivalence to existing WAKIX tablets and supporting plans to file a New Drug Application in early 2026 with a potential review decision in the first quarter of 2027.\nBy pairing these GR data with high-dose pitolisant development and patent applications that could extend exclusivity to 2044, Harmony is reinforcing the long-term durability of its...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/harmony-biosciences-hrmy-is-up-76-after-gr-pitolisant-bioequ","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/harmony-biosciences-hrmy-is-up-76-after-gr-pitolisant-bioequ","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HRMY","BK4007"],"gpt_icon":0},{"id":"2588053716","title":"Harmony Biosciences Unveils New Phase 3 ARGUS Trial Data on EPX-100 for Dravet Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053716","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053716?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:05","pubTimestamp":1764680721,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings Inc. has announced that new open-label extension data from its ongoing Phase 3 ARGUS trial investigating EPX-100  for the treatment of Dravet syndrome will be presented at the 2025 American Epilepsy Society Annual Meeting. The meeting will take place from December 5 to December 9, 2025, in Atlanta, Georgia. Poster presentations are scheduled for Monday, December 8, with topics including preliminary results from the open-label extension phase of the ARGUS study and a drug-drug interaction study of EPX-100 with clinical probe substrates for selected CYP enzymes. The ARGUS trial is currently enrolling participants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDLb8fP9X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY","BK4007"],"gpt_icon":0},{"id":"2588372799","title":"Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2588372799","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588372799?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:43","pubTimestamp":1764592990,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings (HRMY) has an average rating of buy and mean price target of $46.18, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MFG","HRMY"],"gpt_icon":0},{"id":"2588217287","title":"Harmony Biosciences : Mizuho Raises Target Price to $46 From $39","url":"https://stock-news.laohu8.com/highlight/detail?id=2588217287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588217287?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:35","pubTimestamp":1764588928,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70H1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HRMY","BK4007"],"gpt_icon":0},{"id":"2586279104","title":"Harmony Biosciences Holdings (HRMY) Is Up 6.8% After Positive Pitolisant Study Results Are Patent Hopes Justified?","url":"https://stock-news.laohu8.com/highlight/detail?id=2586279104","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586279104?lang=en_us&edition=fundamental","pubTime":"2025-11-28 07:30","pubTimestamp":1764286208,"startTime":"0","endTime":"0","summary":"Earlier this week, Harmony Biosciences Holdings announced positive pivotal bioequivalence study results for its new pitolisant gastro-resistant formulation, setting the stage for a planned New Drug Application submission in early 2026.\nWith patent applications potentially extending pitolisant exclusivity to 2044, the company is aiming to reinforce its leadership position in sleep disorder therapeutics.\nWe'll explore how the bioequivalence study success and anticipated regulatory milestones...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/harmony-biosciences-holdings-hrmy-is-up-68-after-positive-pi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/harmony-biosciences-holdings-hrmy-is-up-68-after-positive-pi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HRMY","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.harmonybiosciences.com","stockEarnings":[{"period":"1week","weight":-0.0604},{"period":"1month","weight":-0.066},{"period":"3month","weight":0.3985},{"period":"6month","weight":0.029},{"period":"1year","weight":-0.0602},{"period":"ytd","weight":-0.0321}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.036948},{"month":2,"riseRate":0.4,"avgChangeRate":-0.018327},{"month":3,"riseRate":0.4,"avgChangeRate":-0.016579},{"month":4,"riseRate":0,"avgChangeRate":-0.07831},{"month":5,"riseRate":0.6,"avgChangeRate":0.050645},{"month":6,"riseRate":0.6,"avgChangeRate":-0.007672},{"month":7,"riseRate":0.8,"avgChangeRate":0.041515},{"month":8,"riseRate":0.8,"avgChangeRate":0.05943},{"month":9,"riseRate":0.5,"avgChangeRate":-0.023406},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.006378},{"month":11,"riseRate":0.833333,"avgChangeRate":0.105341},{"month":12,"riseRate":0.5,"avgChangeRate":0.02881}],"exchange":"NASDAQ","name":"Harmony Biosciences Holdings, Inc.","nameEN":"Harmony Biosciences Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Harmony Biosciences Holdings, Inc.(HRMY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Harmony Biosciences Holdings, Inc.(HRMY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Harmony Biosciences Holdings, Inc.,HRMY,Harmony Biosciences Holdings, Inc.股票,Harmony Biosciences Holdings, Inc.股票老虎,Harmony Biosciences Holdings, Inc.股票老虎国际,Harmony Biosciences Holdings, Inc.行情,Harmony Biosciences Holdings, Inc.股票行情,Harmony Biosciences Holdings, Inc.股价,Harmony Biosciences Holdings, Inc.股市,Harmony Biosciences Holdings, Inc.股票价格,Harmony Biosciences Holdings, Inc.股票交易,Harmony Biosciences Holdings, Inc.股票购买,Harmony Biosciences Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Harmony Biosciences Holdings, Inc.(HRMY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Harmony Biosciences Holdings, Inc.(HRMY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}